Here, we retrospectively analyzed the efficacy of chemotherapy and molecular targeted therapy in patients with advanced or metastatic PPC, and characterized their somatic alteration status, particularly for EGFR mutation, K-ras mutation, and ALK immunohistochemistry (IHC). The gene discussed is KRAS; the disease is primary peritoneal carcinoma.